1. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects
Akizawa et al. Am J Nephrol 2017;45:   (DOI: / )
Table 1. Demographic and clinical characteristics (safety population)

2. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects
Akizawa et al. Am J Nephrol 2017;45:   (DOI: / )
Fig. 1. CONSORT flow chart.

3. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects
Akizawa et al. Am J Nephrol 2017;45:   (DOI: / )
Table 2. Baseline values and mean changes in hemoglobin (intent-to-treat population)

4. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects
Akizawa et al. Am J Nephrol 2017;45:   (DOI: / )
Fig. 2. Mean hemoglobin changes over time (intent-to-treat population; mean ± SD).

5. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects
Akizawa et al. Am J Nephrol 2017;45:   (DOI: / )
Table 3. Pharmacokinetic exposure parameters, peak EPO, and peak VEGF concentrations (intent-to-treat population)

6. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects
Akizawa et al. Am J Nephrol 2017;45:   (DOI: / )
Table 4. Baseline values and changes from baseline in ferritin, transferrin, TIBC, total iron, hepcidin, and transferrin saturation (intent-to-treat population)